Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase Ib Clinical Study of CD19 CAR-T Expressing IL-7 and CCL19 Combined With Tislelizumab in the Treatment of Relapsed/Refractory Diffuse Large B-cell Lymphoma

NCT05659628 is registered in ClinicalTrials.gov with Ningbo No. 1 Hospital as lead sponsor.

NCT NCT05659628
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05659628 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase Ib Clinical Study of CD19 CAR-T Expressing IL-7 and CCL19 Combined With Tislelizumab in the Treatment of Relapsed/Refractory Diffuse Large B-cell Lymphoma
Lead sponsor
Ningbo No. 1 Hospital
Phase
Phase 1
Overall status
Recruiting
Start date
December 31, 2022
Completion date
December 31, 2026
Enrollment
24 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

diffuse large b-cell lymphoma